Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean W Felsher

Showing results (101-110 of 146) with videos related to

Pageof 15
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2006
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switchSylvie Giuriato, Sandra Ryeom, Alice C Fan, et al.
Cancer Cell|September 6, 2007
HIF-dependent antitumorigenic effect of antioxidants in vivoPing Gao, Huafeng Zhang, Ramani Dinavahi, et al.
Plos One|May 8, 2008
Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomasPhuoc T Tran, Alice C Fan, Pavan K Bendapudi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 22, 2009
Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult miceShelly Beer, David I Bellovin, Joyce S Lee, et al.
Nature Communications|June 7, 2020
MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignanciesSrividya Swaminathan, Aida S Hansen, Line D Heftdal, et al.
Cancer Cell|March 22, 2014
Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistanceZhongwei Cao, Bi-Sen Ding, Peipei Guo, et al.
Cancer Research|July 4, 2019
<i>MYC</i> Regulates the <i>HIF2α</i> Stemness Pathway via <i>Nanog</i> and <i>Sox2</i> to Maintain Self-Renewal in Cancer Stem Cells versus Non-Stem Cancer CellsBikul Das, Bidisha Pal, Rashmi Bhuyan, et al.
Cancer Research|July 3, 2008
Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenanceCatherine M Shachaf, Andrew J Gentles, Sailaja Elchuri, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2004
The human BCL6 transgene promotes the development of lymphomas in the mouseBeverly W Baron, John Anastasi, Anthony Montag, et al.
Science Translational Medicine|October 7, 2011
Survival and death signals can predict tumor response to therapy after oncogene inactivationPhuoc T Tran, Pavan K Bendapudi, H Jill Lin, et al.
Pageof 15

Showing results (101-110 of 146) with videos related to

Sort By:
Pageof 15
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2006
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switchSylvie Giuriato, Sandra Ryeom, Alice C Fan, et al.
Cancer Cell|September 6, 2007
HIF-dependent antitumorigenic effect of antioxidants in vivoPing Gao, Huafeng Zhang, Ramani Dinavahi, et al.
Plos One|May 8, 2008
Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomasPhuoc T Tran, Alice C Fan, Pavan K Bendapudi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 22, 2009
Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult miceShelly Beer, David I Bellovin, Joyce S Lee, et al.
Nature Communications|June 7, 2020
MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignanciesSrividya Swaminathan, Aida S Hansen, Line D Heftdal, et al.
Cancer Cell|March 22, 2014
Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistanceZhongwei Cao, Bi-Sen Ding, Peipei Guo, et al.
Cancer Research|July 4, 2019
<i>MYC</i> Regulates the <i>HIF2α</i> Stemness Pathway via <i>Nanog</i> and <i>Sox2</i> to Maintain Self-Renewal in Cancer Stem Cells versus Non-Stem Cancer CellsBikul Das, Bidisha Pal, Rashmi Bhuyan, et al.
Cancer Research|July 3, 2008
Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenanceCatherine M Shachaf, Andrew J Gentles, Sailaja Elchuri, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2004
The human BCL6 transgene promotes the development of lymphomas in the mouseBeverly W Baron, John Anastasi, Anthony Montag, et al.
Science Translational Medicine|October 7, 2011
Survival and death signals can predict tumor response to therapy after oncogene inactivationPhuoc T Tran, Pavan K Bendapudi, H Jill Lin, et al.
Pageof 15